Company

Stylus Medicine, Inc.

Stylus Medicine develops in vivo genetic medicines, including potential CAR-T therapies.

About

Founded in 2022, Stylus Medicine develops in vivo genetic medicines for oncology and autoimmune diseases. Its work includes engineered recombinases and cell-targeted lipid nanoparticle delivery for in vivo CAR-T therapies. The company is based in Cambridge, US, and reported USD 0.052 mn in funding from a June 10, 2024 deal. Its planned work includes further development of these therapies.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in